VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VNDA

<< 前へ 1 2 3 4 5 6 7 8 9 10 11 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/17	22 : 02	PR Newswire (US)	Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/03	23 : 25	AllPennyStocks.com	Biotech Catches Major Premarket Bid Following FDA Approval	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/03	07 : 10	PR Newswire (US)	Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/08	06 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/06	21 : 00	PR Newswire (US)	Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/17	06 : 31	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/08	21 : 19	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/08	06 : 07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/08	06 : 02	PR Newswire (US)	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/06	06 : 34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/05	22 : 00	PR Newswire (US)	Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/01	06 : 30	PR Newswire (US)	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/01/31	23 : 00	PR Newswire (US)	Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/01/31	02 : 35	PR Newswire (US)	Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024	NASDAQ:VNDA	Vanda Pharmaceuticals Inc